How to Fight Insurance Denials for Hepatitis C Treatment

Hepatitis C is curable. Direct-acting antiviral (DAA) regimens like Mavyret, Epclusa, Vosevi, and Harvoni achieve 97–99% cure rates in 8–12 weeks, yet insurers routinely deny them. The drugs cost $25,000–$35,000 wholesale, so plans impose restrictions that contradict medical guidelines: they demand proof of advanced liver damage before they'll pay, require six months of documented sobriety, insist you try an older or less-appropriate regimen first, or say only a specialist can prescribe. These barriers are not rooted in science—the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) recommend treating all patients with chronic HCV, regardless of fibrosis stage, substance use, or prescriber type. This guide walks you through the most common denial templates, the authoritative citations that overturn them, and concrete steps to win your appeal.

---

Why Insurers Deny Hepatitis C Treatment

Insurers use a rotating set of clinical and administrative barriers to ration access to DAAs. The four most common denial templates are:

1. Fibrosis-stage gating ("Not sick enough yet")

The plan requires F3–F4 fibrosis (advanced scarring or cirrhosis) before approving treatment. Denials say "medical necessity criteria not met" or "policy requires moderate to severe liver disease." This ignores AASLD/IDSA guidance to treat all patients, and it contradicts the evidence that early treatment prevents progression to cirrhosis, liver cancer, and need for transplant.

2. Sobriety and substance-use requirements

The denial demands six or twelve months of documented abstinence from alcohol or drugs, urine drug screens, or enrollment in a monitored addiction program. Language includes "active substance use is a contraindication" or "patient must demonstrate adherence capability." This directly contradicts AASLD/IDSA, which states that active or recent drug use is not a contraindication and that treating people who inject drugs is a public-health priority to reduce transmission.

3. Step-therapy and formulary restrictions

The plan insists you try a different, often older or narrower-spectrum DAA first—such as requiring Harvoni before Mavyret, or demanding a genotype-specific regimen when a pangenotypic one is prescribed. These steps may not match your clinical situation (prior failure, genotype, cirrhosis status, drug interactions) and can delay cure or risk treatment failure.

4. Prescriber restrictions ("Specialist required")

The denial says hepatitis C treatment must be managed by a gastroenterologist, hepatologist, or infectious disease specialist, and refuses coverage for prescriptions written by primary care physicians or advanced practice providers. AASLD/IDSA explicitly endorses primary-care management of uncomplicated HCV, and many rural or underserved patients have no local specialist access.

5. Reinfection-risk or adherence concerns

Insurers occasionally deny treatment citing "high risk of reinfection" (ongoing injection drug use, incarceration) or vague "concerns about adherence." These are not evidence-based contraindications and are often pretexts to avoid paying for cure in populations the plan perceives as costly.

---

The Citations Insurers Respect

Appeals succeed when you anchor arguments in authoritative, named guidelines and trial data. Do not let the insurer rely on vague internal "medical policy." Cite these resources by full name and year:

Clinical guidelines (load-bearing)

• AASLD/IDSA HCV Guidance (jointly with IAS-USA, continuously updated at hcvguidelines.org): The gold standard. States unequivocally: "Treatment is recommended for all patients with acute or chronic HCV infection, including pregnant persons, except those with a short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or another directed therapy."

- On substance use: "Active or recent drug use or a concern for reinfection is not a contraindication to HCV treatment."

- On prescribers: "Clinicians with experience treating HCV—including primary care providers, advanced practice providers, and specialists—can effectively manage uncomplicated HCV."

• USPSTF 2020 Hepatitis C Screening Recommendation (Grade B): Universal one-time screening for adults 18–79. Triggers Affordable Care Act §2713 coverage for screening (not treatment, but buttresses the case for early detection and cure).

• CDC 2020 Universal Screening Recommendation: Adults 18+ and all pregnant persons each pregnancy. Reinforces public-health imperative.

Pivotal trials (pangenotypic DAAs)

• ENDURING-1 and SURVEYOR-II (Mavyret for treatment-naive and treatment-experienced patients): Published in New England Journal of Medicine 2017 and Hepatology 2017. Demonstrated 97–100% SVR12 (cure) across genotypes 1–6, including patients with compensated cirrhosis, in 8–12 weeks.

• ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 (Epclusa trials, NEJM 2015–2016): Sofosbuvir/velpatasvir 12 weeks achieved 95–99% SVR12 across all six major genotypes, including patients with decompensated cirrhosis (ASTRAL-4 with ribavirin).

• POLARIS-1 and POLARIS-4 (Vosevi for DAA-experienced patients, NEJM 2017): Sofosbuvir/velpatasvir/voxilaprevir achieved 96–98% cure in patients who failed prior NS5A inhibitor or sofosbuvir regimens.

Legal and policy precedent

• B.E. v. Teeter, No. C16-227-JCC (W.D. Wash. May 27, 2016): Class-action case that struck down Washington State Medicaid's F3+ fibrosis restriction as violating the federal Medicaid Act. The injunction required the state to cover DAAs for all fibrosis stages. Similar suits succeeded in Delaware, Massachusetts, Florida, Indiana, and Colorado.

• CMS Medicaid Drug Rebate Program Notice CPI-MM-2015-01 (November 2015): Federal guidance warning state Medicaid programs that limiting DAAs by fibrosis stage or sobriety status may violate the Medicaid Act's reasonable-standards and EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

• National Health Law Program (NHeLP) and Harvard CHLPI "Hepatitis C: State of Medicaid Access" Report Card: Tracks state-by-state restrictions. Documents that most sobriety and fibrosis barriers have been formally removed, though de facto application persists.

Drug labels and approvals

• FDA-approved indications: Mavyret, Epclusa, and Vosevi are approved for all genotypes and do not require genotype testing. Harvoni is genotype-restricted (GT 1, 4, 5, 6). All four are approved across fibrosis stages F0–F4.

---

How to Argue Against Each Denial Reason

Fighting "Not sick enough yet" (fibrosis-stage denials)

Core argument: AASLD/IDSA recommend treating all patients with chronic HCV, explicitly including those with no or minimal fibrosis (F0–F2). Delaying treatment until cirrhosis develops is not evidence-based care—it is rationing that increases long-term costs (cirrhosis management, liver cancer surveillance, transplant) and patient harm.

Concrete steps:

1. Quote the AASLD/IDSA guidance verbatim in your appeal letter: "Treatment is recommended for all patients with acute or chronic HCV infection…" Emphasize that fibrosis stage is not a gating criterion in the clinical standard of care.

2. Include your fibrosis assessment: Provide FIB-4 score, FibroScan (transient elastography) result in kPa, or biopsy METAVIR stage if available. Even if you are F0–F2, state: "Current fibrosis stage does not alter the indication for treatment per AASLD/IDSA."

3. Cite cost-effectiveness literature: Early treatment prevents progression and is cost-effective. Reference CDC's viral hepatitis elimination goals and note that untreated HCV progresses to cirrhosis in 15–30% of patients over 20 years, with attendant costs exceeding DAA therapy.

4. Invoke B.E. v. Teeter and CMS guidance if you have Medicaid or a plan subject to similar standards. State: "Federal courts and CMS have ruled that fibrosis restrictions in Medicaid violate the Medicaid Act. [Plan name] policy is out of step with legal and clinical standards."

5. Request an Independent Medical Review (IMR) or External Review if your state offers it. Many state regulators side with patients when the plan's policy contradicts AASLD/IDSA.

---

Fighting sobriety and substance-use requirements

Core argument: AASLD/IDSA explicitly state that active or recent drug use is not a contraindication. Requiring documented sobriety is discriminatory, delays cure, perpetuates transmission, and contradicts harm-reduction principles endorsed by CDC and public-health authorities.

Concrete steps:

1. Quote AASLD/IDSA verbatim in the appeal: "Active or recent drug use or a concern for reinfection is not a contraindication to HCV treatment." State that treating people who inject drugs (PWID) reduces community viral load and is a cornerstone of HCV elimination strategies.

2. Provide context for your situation: If you are in a medication-assisted treatment (MAT or MOUD) program, on buprenorphine or methadone, or receiving harm-reduction services, note this. If you are not actively using but the plan imposed a retrospective sobriety requirement, state that clearly. Either way, emphasize that substance use status does not predict treatment adherence or SVR in published cohorts.

3. Cite real-world evidence: Numerous studies (e.g., SIMPLIFY, C-EDGE CO-STAR) demonstrate that DAA cure rates in PWID are comparable to the general population (>95%). Mention CDC and WHO endorsements of treating PWID without delay.

4. Invoke anti-discrimination arguments: If your plan is an ACA marketplace or employer plan subject to Mental Health Parity and Addiction Equity Act (MHPAEA), note that singling out patients with substance-use disorders for additional barriers may violate parity rules. If Medicaid, reference B.E. v. Teeter and CMS guidance.

5. Highlight reinfection is manageable and rare: Post-cure reinfection rates in PWID cohorts are 1–5% per year. Reinfection is treatable with the same or alternative DAA. Denying initial cure to avoid theoretical reinfection is not clinically or ethically defensible.

---

Fighting step-therapy and formulary games

Core argument: AASLD/IDSA provide regimen-selection guidance based on genotype, treatment history, cirrhosis status, and comorbidities (HIV, HBV, CKD). Forcing a patient to fail an inappropriate or inferior regimen first is not evidence-based step therapy—it risks treatment failure, resistance, and harm.

Concrete steps:

1. Match your regimen to AASLD/IDSA recommendations:

- Treatment-naive, no cirrhosis or compensated cirrhosis (Child-Pugh A): Mavyret 8 weeks or Epclusa 12 weeks are both first-line pangenotypic options. Harvoni is narrower (GT 1, 4, 5, 6 only) and no longer preferred unless there is a specific drug-interaction reason.

- Decompensated cirrhosis (Child-Pugh B/C): Epclusa + ribavirin 12 weeks. Protease inhibitors (including the glecaprevir in Mavyret) are contraindicated in decompensated cirrhosis.

- Prior DAA failure (NS5A or NS3 inhibitor): Vosevi 12 weeks is the preferred salvage regimen (POLARIS trials).

2. State why the plan's preferred alternative is inappropriate:

- "Plan requires trial of Harvoni, but AASLD/IDSA list Mavyret and Epclusa as co-equal pangenotypic first-line options. Harvoni does not cover all genotypes and offers no clinical advantage here."

- "Plan requires Mavyret, but patient has decompensated cirrhosis (Child-Pugh B). Glecaprevir (in Mavyret) is contraindicated per FDA label. Epclusa + ribavirin is the only appropriate regimen."

- "Plan requires re-trial of Epclusa, but patient relapsed after prior Epclusa (NS5A failure). AASLD/IDSA and POLARIS-1 data show Vosevi (adding voxilaprevir) is the evidence-based salvage regimen."

3. Attach the relevant AASLD/IDSA treatment algorithm screenshot or table from hcvguidelines.org showing your regimen as recommended.

4. Quantify harm and cost of delay: An 8–12 week delay to fail the plan's preferred regimen, then prior-authorize the correct one, then wait for appeal means 4–6 months untreated. Note risk of disease progression, ongoing transmission if you're in a risk group, and the plan's ultimate cost will be higher (two regimens instead of one).

5. Request expedited review if you have decompensated cirrhosis, acute HCV, or another urgent clinical factor.

---

Fighting prescriber restrictions

Core argument: AASLD/IDSA explicitly endorse management by primary care providers (PCPs), nurse practitioners, and physician assistants for uncomplicated HCV. Requiring referral to a scarce specialist delays care, increases costs, and is unnecessary for most patients.

Concrete steps:

1. Quote AASLD/IDSA prescriber guidance verbatim: "Clinicians with experience treating HCV—including primary care providers, advanced practice providers, and specialists—can effectively manage uncomplicated HCV."

2. Define "uncomplicated": You are uncomplicated if you have no or compensated cirrhosis (Child-Pugh A), no prior DAA failure requiring salvage therapy, and no complex drug interactions (e.g., certain HIV regimens). State: "My case meets AASLD/IDSA criteria for primary-care management."

3. Document your prescriber's qualifications: Note if your PCP has prescribed DAAs before, completed Project ECHO or AASLD training, or comanages with a specialist via telemedicine or curbside. Even a single prior DAA prescription demonstrates "experience."

4. Highlight access barriers: If you live in a rural area, have transportation limitations, or face months-long wait times for a hepatologist, state this. Note that the plan's restriction effectively denies you timely care.

5. Cite workforce and public-health arguments: HCV elimination requires expanding the prescriber pool beyond specialists. CDC, AASLD, and IDSA all endorse task-shifting to primary care as essential to reaching underserved populations.

6. Offer compromise if needed: Propose your PCP consult with a hepatologist (via phone, telehealth, or e-consult) for initial regimen selection, but that ongoing management and prescription remain with your PCP. Many plans accept this "comanagement" model.

---

What We Do

We help patients draft medical-necessity appeal letters that cite the correct clinical guidelines, match your case to the authoritative evidence, and counter the insurer's boilerplate denial language with specific, cited rebuttals. We don't practice medicine—we translate your physician's clinical reasoning into the appeal format and evidentiary standard that wins. We also help you navigate state external review, file complaints with your state insurance commissioner or Medicaid office when plans ignore guidelines, and coordinate with your provider to submit supplemental documentation. Hepatitis C is curable, and your insurance is contractually and often legally obligated to pay for that cure. We make sure they do.

---

Sources

1. AASLD/IDSA/IAS-USA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Updated continuously. https://www.hcvguidelines.org

2. US Preventive Services Task Force. Hepatitis C Virus Infection in Adolescents and Adults: Screening. JAMA. 2020;323(10):970–975. doi:10.1001/jama.2020.1123

3. Centers for Disease Control and Prevention. Hepatitis C Questions and Answers for Health Professionals. Updated April 2020. https://www.cdc.gov/hepatitis/hcv/

4. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354–369. (ENDURING-1, SURVEYOR-II consolidation)

5. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599–2607. (ASTRAL-1)

6. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373(27):2608–2617. (ASTRAL-2, ASTRAL-3)

7. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373(27):2618–2628. (ASTRAL-4)

8. Bourlière M, Gordon SC, Flamm SL, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376(22):2134–2146. (POLARIS-1, POLARIS-4)

9. B.E. v. Teeter, No. C16-227-JCC (W.D. Wash. May 27, 2016). Class-action preliminary injunction against Washington State Medicaid HCV treatment restrictions.

10. Centers for Medicare & Medicaid Services. Assuring Medicaid Beneficiaries Access to Hepatitis C (HCV) Drugs. CMCS Informational Bulletin, CPI-MM-2015-01. November 5, 2015.

11. National Health Law Program and Harvard Center for Health Law and Policy Innovation. Hepatitis C: State of Medicaid Access – National Summary Report. October 2022. https://healthlaw.org/hepatitisc/

12. Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153–161.

13. Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016;165(9):625–634. (C-EDGE CO-STAR)

14. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. July 2018. Geneva: WHO.

---

Disclaimer: This guide is educational and does not constitute medical or legal advice. Appeal strategies should be tailored to your specific clinical situation, insurance plan, and state law. Work with your treating physician and consider consulting a patient advocate or attorney if your appeal is denied at all levels.